Pridopidine is a novel small molecule sigma-1 receptor (σ1R) agonist being developed by Prilenia Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS). The Phase 3 trial (NCT07322003) represents one of the most advanced clinical programs targeting the sigma-1 receptor in ALS, a protein implicated in cellular homeostasis, calcium regulation, and neuroprotection.
This randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of pridopidine in approximately 500 participants with ALS over a 48-week treatment period. The trial uses the Revised ALS Functional Rating Scale (ALSFRS-R) as the primary endpoint, with the primary analysis focusing on change from baseline through Week 26 and Week 48, adjusted for mortality[@prilenia].
| Parameter | Value |
|---|---|
| NCT Number | NCT07322003 |
| Phase | Phase 3 |
| Status | RECRUITING (as of early 2026) |
| Sponsor | Prilenia Therapeutics |
| Enrollment | 500 participants (estimated) |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Allocation | Randomized, double-blind, placebo-controlled |
| Start Date | February 2026 |
| Completion Date | March 2029 |
| Last Updated | February 2026 |
Pridopidine's therapeutic potential in ALS derives from its activity as a selective sigma-1 receptor agonist. The sigma-1 receptor is a chaperone protein located primarily in the endoplasmic reticulum (ER) that plays critical roles in cellular homeostasis:
Calcium Homeostasis Regulation
Endoplasmic Reticulum Stress Response
Mitochondrial Function Preservation
Neuroinflammation Modulation
The sigma-1 receptor has been validated as a therapeutic target in ALS through extensive preclinical work:
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial representing the final stage of clinical evaluation for pridopidine in ALS.
| Arm | Intervention | Dose |
|---|---|---|
| Active | Pridopidine oral | 45 mg twice daily (90 mg total) |
| Control | Placebo oral | Matching twice daily |
The 45 mg twice-daily dose was selected based on Phase 2 dose-ranging work showing tolerability and target engagement.
The ALSFRS-R is the gold-standard functional assessment in ALS, measuring:
A 1-point change on ALSFRS-R is considered clinically meaningful.
The sigma-1 receptor (σ1R) represents a unique molecular target in neurodegenerative disease, distinct from other well-characterized drug targets. This 223-amino acid protein is primarily localized to the endoplasmic reticulum (ER) membrane, where it functions as a molecular chaperone and calcium modulator with broad implications for cellular homeostasis[@marin2022].
The σ1R belongs to the ER membrane protein complex that includes the BAP (-binding immunoglobulin protein) and the σ1 receptor itself. Its structure reveals:
Calcium dysregulation is a central feature of ALS pathogenesis. Motor neurons have particularly high calcium requirements due to their extensive axonal projections and high firing rates. σ1R modulates calcium in multiple ways:
ER-Mitochondria Coupling: The σ1R physically couples to the mitochondrial calcium uniporter (MCU) complex, regulating calcium transfer from ER to mitochondria. This coupling is critical because:
Store-Operated Calcium Entry: σ1R activity modulates plasma membrane calcium channels, affecting how neurons respond to synaptic activity.
The σ1R plays critical roles in protein quality control, relevant to ALS where protein aggregation is a hallmark:
Unfolded Protein Response: During ER stress, σ1R Expression increases and the receptor assists in protein folding. However, chronic ER stress leads to apoptosis—σ1R agonism may help restore homeostasis.
Autophagy Regulation: σ1R interacts with autophagy machinery, promoting clearance of protein aggregates. This is particularly relevant given TDP-43 aggregation in most ALS cases.
Protein Degradation: σ1R facilitates ubiquitinated protein handling, potentially helping clear misfolded proteins before they accumulate.
Beyond direct neuronal effects, σ1R modulates neuroinflammation, a key driver of ALS progression:
Microglial Polarization: σ1R agonists promote the anti-inflammatory (M2) microglial phenotype over the pro-inflammatory (M1) phenotype. This shifts the microenvironment from damaging to protective.
Cytokine Regulation: σ1R activation reduces TNF-α, IL-1β, and other pro-inflammatory cytokines while increasing anti-inflammatory IL-10.
T Cell Modulation: The adaptive immune response is also modulated, potentially reducing autoimmune components.
The genetic link between σ1R and ALS strengthens the therapeutic rationale:
SIGMAR1 Mutations: Loss-of-function mutations in SIGMAR1 (the gene encoding σ1R) cause a juvenile-onset form of ALS/FTD. These mutations demonstrate that:
Modifiers: SIGMAR1 polymorphisms may modify ALS progression in sporadic cases, suggesting it plays a role in disease severity.
Understanding whether pridopidine actually engages its molecular target in patients is critical for interpreting trial results:
While direct measurement of σ1R occupancy in humans is challenging, several approaches may inform target engagement:
Functional Biomarkers: σ1R activation affects calcium handling, ER stress markers, and inflammatory cytokines. Changes in these parameters may serve as indirect measures of target engagement.
PK/PD Relationships: Pharmacokinetic measurements can establish exposure-response relationships that inform whether adequate target engagement is achieved.
NfL in plasma/serum is a key biomarker in ALS trials:
Biological Basis: When motor neurons are damaged, neurofilament proteins leak into the bloodstream. Higher NfL levels indicate more rapid neurodegeneration.
Prognostic Value: Baseline NfL strongly predicts progression rate and survival in ALS.
Treatment Effects: A drug that slows neurodegeneration should reduce the rate of NfL increase over time.
Utility in Pridopidine Trial: The secondary endpoint includes NfL, allowing assessment of whether pridopidine slows axonal degeneration.
| Biomarker | What It Measures | Utility |
|---|---|---|
| pNfH (phosphorylated neurofilament heavy chain) | Axonal damage severity | Prognostic |
| Cystatin C | Kidney function, ALS progression | Safety + efficacy |
| Creatinine | Muscle mass, disease stage | Prognostic |
| Urine p75ECD | Motor neuron injury | Investigational |
The FDA has provided guidance specifically for ALS clinical trials:
Companion Diagnostic: Not required as σ1R agonism is not genotype-specific
Accelerated Approval: Could be considered if NfL shows strong treatment effect as surrogate endpoint
Real-World Evidence: May supplement randomized data post-approval
The trial likely includes sites across multiple regulatory jurisdictions:
| Region | Regulatory Body | Considerations |
|---|---|---|
| US | FDA | Fast Track designation may priority review |
| EU | EMA | PRIME designation possible |
| Japan | PMDA | Conditional approval pathway |
ALS remains one of the most challenging neurodegenerative diseases to treat. The current treatment landscape includes:
| Treatment | Mechanism | Efficacy |
|---|---|---|
| Riluzole | Glutamate modulation | ~2-3 month survival benefit |
| Edaravone | Antioxidant | Slows functional decline in specific patients |
| Tofersen | SOD1 gene therapy | Slows decline in SOD1 mutation carriers |
| AMIASRS | CNTF expression | Investigational |
| Pridopidine | σ1R agonist | Phase 3 ongoing |
ALS trials face significant obstacles that pridopidine must overcome:
The trial's use of rank-based analysis adjusts for mortality, a critical issue in ALS trials.
ALS pathogenesis involves multiple parallel pathways, suggesting that targeting several simultaneously may provide greater benefit than any single mechanism alone:
| Combination | Potential Benefit | Rationale |
|---|---|---|
| Pridopidine + Riluzole | Neuroprotection + glutamate modulation | Multiple pathways, established safety |
| Pridopidine + Edaravone | σ1R + antioxidant | Complementary oxidative stress reduction |
| Pridopidine + Tofersen | Broad + genetic-specific | SOD1 + sporadic mechanisms |
If pridopidine is approved, the likely treatment paradigm would be:
This would represent a multi-mechanism approach to ALS treatment that was previously unavailable.
Several companies have expressed interest in combination approaches, but significant challenges remain:
For patients interested in participating in NCT07322003:
The trial specifically enrolls patients with:
Visits: Approximately 10-12 visits over 48 weeks for assessments
Travel: Multi-center design means patients can often find nearby sites
Compensation: Typically provided for time and travel
For patients who cannot access the trial:
Prilenia may offer:
ALS treatment involves substantial healthcare resources:
| Cost Category | Annual Cost (US) |
|---|---|
| Medications | $10,000-180,000 |
| Equipment | $5,000-50,000 |
| Home care | $50,000-200,000 |
| Facility care | $100,000-300,000 |
Pricing discussions for ALS therapies consider:
Before initiating the Phase 3 registration trial, Prilenia conducted important dose-finding work in the HPRD01 study, which established the clinical foundation for NCT07322003:
| Parameter | HPRD01 |
|---|---|
| Phase | Phase 2 |
| Design | Randomized, double-blind, placebo-controlled |
| Doses | Multiple doses to establish dose-response |
| Duration | 26 weeks |
| Population | ALS patients meeting similar criteria to Phase 3 |
The HPRD01 study provided several critical insights:
Dose Selection: The 45 mg BID dose was identified as optimal based on both efficacy signals and tolerability, establishing the dosing regimen for Phase 3[@gline2024].
Safety Profile: The compound showed acceptable safety at all doses tested, with no unexpected adverse events that would preclude advancement.
Efficacy Signals: While not powered for formal statistical significance, the study showed directional benefits in ALSFRS-R slope compared to placebo that informed the Phase 3 sample size calculation.
Target Engagement: Biomarker analyses suggested biological activity consistent with σ1R agonism.
The Phase 3 trial design incorporates several lessons from HPRD01:
Understanding how pridopidine-treated patients compare to untreated natural history is critical for interpretation:
In ALS natural history studies, untreated patients typically show:
If pridopidine achieves:
The clinical significance of these changes is substantial:
| Effect | Patients Maintaining Function | Approximate Benefit |
|---|---|---|
| 25% slower | +4-6 months of independence | Meaningful quality of life |
| 50% slower | +8-12 months | Substantial milestone |
Several factors complicate interpretation:
Understanding the drug's behavior in humans informs interpretation:
| Parameter | Value |
|---|---|
| Absorption | Rapid oral absorption |
| Tmax | 1-3 hours |
| Half-life | ~8-12 hours |
| Steady State | 3-5 days |
| Protein Binding | High (>95%) |
| Metabolism | Hepatic (CYP-mediated) |
| Excretion | Renal |
Pridopidine may interact with:
The relationship between exposure and response is critical:
Understanding outcomes and next steps:
Should NCT07322003 meet its primary endpoint:
If the trial fails to meet its primary endpoint:
Ensuring continued access for patients who benefit:
The ALS therapeutic landscape is evolving rapidly:
| Drug | Company | Mechanism | Stage |
|---|---|---|---|
| Tofersen | Biogen | SOD1 ASO | Approved (2023) |
| BIIB059 | Biogen | Immune modulation | Phase 2 |
| ABTV-3376 | Avid Bioservices | Gene therapy | Phase 1 |
| Pridopidine | Prilenia | σ1R agonist | Phase 3 |
| CNTNAP2 ASO | Roche | Genetic | Phase 1 |
The trial is being conducted at major ALS centers globally, including:
Pridopidine received Fast Track designation from the FDA in 2023, acknowledging:
The drug has also received orphan drug designation, providing: